Sterling B Ortega

Dr. Sterling B Ortega


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2007 in Clinical Immunology
Verified
Journal Article
Closed access
VPVinodh Pillai
Vinodh Pillai
SOSterling B Ortega
Sterling B Ortega
CWC.K. Wang
C.K. Wang
NKNitin J. Karandikar
Nitin J. Karandikar

1 June 2004 in Blood
Verified
Journal Article
Closed access
MCMichael P. Crawford
Michael P. Crawford
SYShirley X. Yan
Shirley X. Yan
SOSterling B Ortega
Sterling B Ortega
RMRiyaz S. Mehta
Riyaz S. Mehta
RHRachel E. Hewitt
Rachel E. Hewitt
NKNitin J. Karandikar
Nitin J. Karandikar
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system (CNS) with features suggestive of T-cell-mediated pathology. Most prior reports have focused on CD4+ T cells with the underlying assumption that MS is predominantly a CD4+ T helper 1 (Th1)-mediated disease. In this report, we used a novel flow cytometric approach to evaluate autoreactive T-cell responses against a large variety of neuroantigenic targets. We found that both CD4+ and CD8+ T cells targeted against several CNS autoantigens were widely prevalent in patients with MS and healthy individuals. Whereas the distribution of CD4+ responses was similar in different groups, patients with relapsing-remitting MS showed a higher proportion of CNS-specific CD8+ responses. Autoreactive CD4+ T cells from patients with MS exhibited a more differentiated Th1 phenotype compared with healthy subjects. Similarly, CNS-specific CD8+ T-cell responses from patients with MS were functionally distinct from those in healthy individuals. Collectively, these studies reveal the high prevalence of class I-restricted autoreactive CD8+ T-cell responses in MS that has been underappreciated thus far. The results emphasize the need to evaluate both CD4+ and CD8+ T-cell responses in MS and to make both subsets a consideration in the development of novel therapeutic strategies. (Blood. 2004; 103:4222-4231)

1 June 2006 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
DTDeepani K. Tennakoon
Deepani K. Tennakoon
RMRiyaz S. Mehta
Riyaz S. Mehta
SOSterling B Ortega
Sterling B Ortega
VBVijay Bhoj
Vijay Bhoj
MRMichael K. Racke
Michael K. Racke
NKNitin J. Karandikar
Nitin J. Karandikar
In the setting of autoimmunity, one of the goals of successful therapeutic immune modulation is the induction of peripheral tolerance, a large part of which is mediated by regulatory/suppressor T cells. In this report, we demonstrate a novel immunomodulatory mechanism by an FDA-approved, exogenous peptide-based therapy that incites an HLA class I-restricted, cytotoxic suppressor CD8+ T cell response. We have shown previously that treatment of multiple sclerosis (MS) with glatiramer acetate (GA; Copaxone) induces differential up-regulation of GA-reactive CD8+ T cell responses. We now show that these GA-induced CD8+ T cells are regulatory/suppressor in nature. Untreated patients show overall deficit in CD8+ T cell-mediated suppression, compared with healthy subjects. GA therapy significantly enhances this suppressive ability, which is mediated by cell contact-dependent mechanisms. CD8+ T cells from GA-treated patients and healthy subjects, but not those from untreated patients with MS, exhibit potent, HLA class I-restricted, GA-specific cytotoxicity. We further show that these GA-induced cytotoxic CD8+ T cells can directly kill CD4+ T cells in a GA-specific manner. Killing is enhanced by preactivation of target CD4+ T cells and may depend on presentation of GA through HLA-E. Thus, we demonstrate that GA therapy induces a suppressor/cytotoxic CD8+ T cell response, which is capable of modulating in vivo immune responses during ongoing therapy. These studies not only explain several prior observations relating to the mechanism of this drug but also provide important insights into the natural immune interplay underlying this human immune-mediated disease.

1 August 2010 in Journal of Autoimmunity
Verified
Journal Article
Closed access
NYNathan R. York
Nathan R. York
JMJason P. Mendoza
Jason P. Mendoza
SOSterling B Ortega
Sterling B Ortega
ABAndrew Benagh
Andrew Benagh
ATAndrew F. Tyler
Andrew F. Tyler
NKNitin J. Karandikar
Nitin J. Karandikar

1 March 2011 in Journal of Autoimmunity
Verified
Journal Article
Closed access
EBEthan J. Baughman
Ethan J. Baughman
JMJason P. Mendoza
Jason P. Mendoza
SOSterling B Ortega
Sterling B Ortega
CAChris L. Ayers
Chris L. Ayers
BGBenjamin Greenberg
Benjamin Greenberg
NKNitin J. Karandikar
Nitin J. Karandikar

1 July 2013 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
SOSterling B Ortega
Sterling B Ortega
VKVenkatesh P. Kashi
Venkatesh P. Kashi
ATAndrew F. Tyler
Andrew F. Tyler
KCKhrishen Cunnusamy
Khrishen Cunnusamy
JMJason P. Mendoza
Jason P. Mendoza
NKNitin J. Karandikar
Nitin J. Karandikar
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the CNS, and CD8 T cells are the predominant T cell population in MS lesions. Given that transfer of CNS-specific CD8 T cells results in an attenuated clinical demyelinating disease in C57BL/6 mice with immunization-induced experimental autoimmune encephalomyelitis (EAE), we investigated the cellular targets and mechanisms of autoreactive regulatory CD8 T cells. In this study we report that myelin oligodendrocyte glycoprotein peptide (MOG35–55)–induced CD8 T cells could also attenuate adoptively transferred, CD4 T cell–mediated EAE. Whereas CD8−/− mice exhibited more severe EAE associated with increased autoreactivity and inflammatory cytokine production by myelin-specific CD4 T cells, this was reversed by adoptive transfer of MOG-specific CD8 T cells. These autoregulatory CD8 T cells required in vivo MHC class Ia (KbDb) presentation. Interestingly, MOG-specific CD8 T cells could also suppress adoptively induced disease using wild-type MOG35–55-specific CD4 T cells transferred into KbDb−/− recipient mice, suggesting direct targeting of encephalitogenic CD4 T cells. In vivo trafficking analysis revealed that autoregulatory CD8 T cells are dependent on neuroinflammation for CNS infiltration, and their suppression/cytotoxicity of MOG-specific CD4 T cells is observed both in the periphery and in the CNS. These studies provide important insights into the mechanism of disease suppression mediated by autoreactive CD8 T cells in EAE.